Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;199(1):95-99.
doi: 10.1111/bjh.18298. Epub 2022 Jun 13.

Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma

Jithma P Abeykoon  1 , Julia Vaxman  1 , Sanjay V Patel  2 , Shaji Kumar  1 , Gabriella C Malave  1 , Kimberly S Young  1 , Sikander Ailawadhi  3 , Jeremy T Larsen  4 , Angela Dispenzieri  1 , Eli Muchtar  1 , Wilson I Gonsalves  1 , Taxiarchis Kourelis  1 , Nelson Leung  1 , Rahma Warsame  1 , Ronald S Go  1 , Leif Bergsagel  1 , Martha Q Lacy  1 , S Vincent Rajkumar  1 , Morie A Gertz  1 , Prashant Kapoor  1
Affiliations

Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma

Jithma P Abeykoon et al. Br J Haematol. 2022 Oct.

Abstract

Belantamab mafodotin (BLMF) is a B-cell maturation antigen-directed antibody-drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF-induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively seen patients treated with BLMF outside of trials. Of those, 75% experienced ocular toxicity, with 69% developing keratopathy. Among patients requiring ocular toxicity-related permanent BLMF discontinuation (14%) or dose reduction (11%), 70% had progression of MM within a median of 3 months (95% confidence interval: 0.2-not reached) following BLMF interruption or dose reduction. Ocular toxicity is a major deterrent to the continuous use of BLMF in routine clinical practice. Measures to successfully prevent and mitigate ocular toxicity should be developed to achieve the full potential of this agent.

Keywords: B-cell maturation antigen; antibody-drug conjugate; monoclonal gammopathy.

PubMed Disclaimer

References

REFERENCES

    1. Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs. 2018;36(1):121-35.
    1. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9(4):889-911.
    1. Tai Y-T, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128-38.
    1. Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589-604.
    1. Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8(4):659-71.

Publication types

MeSH terms

LinkOut - more resources